Share on StockTwits
 

BioMed Realty Trust (NYSE:BMR) was upgraded by TheStreet from a “hold” rating to a “buy” rating in a research note issued on Thursday, Stock Ratings Network reports.

The analysts wrote, “BioMed Realty (BMR) has been upgraded by TheStreet Ratings from hold to buy. The company’s strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins.”

A number of other analysts have also recently weighed in on BMR. Analysts at Raymond James cut their price target on shares of BioMed Realty Trust from $24.00 to $23.00 in a research note on Friday, February 7th. Analysts at KeyCorp downgraded shares of BioMed Realty Trust from a “buy” rating to a “hold” rating in a research note on Thursday, December 19th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. BioMed Realty Trust has a consensus rating of “Buy” and a consensus price target of $22.67.

Shares of BioMed Realty Trust (NYSE:BMR) traded down 0.39% on Thursday, hitting $20.58. 804,466 shares of the company’s stock traded hands. BioMed Realty Trust has a 1-year low of $17.90 and a 1-year high of $23.13. The stock’s 50-day moving average is $19.54 and its 200-day moving average is $19.01. The company has a market cap of $3.923 billion and a P/E ratio of 103.30.

BioMed Realty Trust (NYSE:BMR) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.02. The company had revenue of $158.00 million for the quarter, compared to the consensus estimate of $157.51 million. During the same quarter in the previous year, the company posted $0.36 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. Analysts expect that BioMed Realty Trust will post $1.44 EPS for the current fiscal year.

BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.